{"id":"NCT00287729","sponsor":"Genentech, Inc.","briefTitle":"Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis","officialTitle":"A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-04","primaryCompletion":"2008-11","completion":"2008-11","firstPosted":"2006-02-07","resultsPosted":"2011-06-13","lastUpdate":"2017-04-17"},"enrollment":344,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Idiopathic Pulmonary Fibrosis"],"interventions":[{"type":"DRUG","name":"Pirfenidone","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"2403 mg/day pirfenidone","type":"ACTIVE_COMPARATOR"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purposes of this study are to assess the efficacy of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis (IPF)and to assess the safety of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis.","primaryOutcome":{"measure":"Absolute Change in Percent Predicted Forced Vital Capacity(FVC)","timeFrame":"Baseline to week 72","effectByArm":[{"arm":"Pirfenidone (2403 mg/d)","deltaMin":-9,"sd":19.58},{"arm":"Placebo","deltaMin":-10,"sd":19.12}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":13},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["37391667","35688625","33434107","31401786","31153107","31047956","30472023","30116539","30072107","28388260","27708114","26968970","26835133","21571362"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":53,"n":171},"commonTop":["Cough","Rash","Idiopathic Pulmonary Fibrosis","Dyspnoea","Headache"]}}